Angelini Ventures Partners in €84M Series B for NUCLIDIUM
Angelini Ventures' Strategic Investment in NUCLIDIUM
- Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors
In an exciting move, Angelini Ventures, part of Angelini Industries and known for its commitment to innovation in BioTech and Digital Health, has come together with several notable investors to co-lead a significant financing round for NUCLIDIUM, totaling CHF 79 million (approximately €84 million). This funding is pivotal for advancing the clinical development of NUCLIDIUM’s proprietary copper-based radiopharmaceutical platform, which stands at the forefront of cancer treatment technologies.
Details of the Financing Round
Co-leading the financing, alongside Kurma Growth Opportunities Fund and Wellington Partners, were additional contributors such as Neva SGR, DeepTech & Climate Fonds, Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK, and HighLight Capital, showcasing a strong belief in NUCLIDIUM's potential. The investment will empower NUCLIDIUM to enhance its strategic direction, focusing on innovative solutions that fill critical gaps in medical needs.
Funding for Clinical Development
The financing will significantly support the clinical development of NUCLIDIUM’s Copper-61/Copper-67 theranostic pipeline, which targets multiple oncology indications. This investment aligns with Angelini Ventures’ strategy to back pioneering companies that address unmet medical requirements in designated patient demographics, fostering significant advancements in healthcare.
Empowering Innovative Solutions
NUCLIDIUM’s unique platform is designed to link tumor-targeting molecules with copper isotopes, specifically Copper-61 for diagnostics and Copper-67 for therapeutic applications. This innovative approach aims to resolve existing challenges in the field of radiotheranostics, such as inadequate clinical efficacy and complicated manufacturing processes. With early-stage clinical trials showing promising results in terms of lesion detection and better tumor-to-background ratios compared to traditional tracers, NUCLIDIUM is set to make a powerful impact in the oncology sector.
NUCLIDIUM’s Vision and Future
Regina Hodits, PhD, Managing Director at Angelini Ventures, expressed enthusiasm about the investment, stating, “We are thrilled to co-lead this financing, affirming our commitment to fueling innovation in healthcare. At Angelini Ventures, we prioritize collaborations that leverage scientific differentiation to address significant unmet needs in the market.” This sentiment underscores a collective hope in precision medicine, which is crucial for the evolution of cancer treatment options.
Commitment to Precision Medicine
Leila Jaafar-Thiel, CEO and Co-founder of NUCLIDIUM, echoed similar sentiments, sharing, “The successful Series B financing round showcases our investors' confidence in NUCLIDIUM's mission to transform cancer diagnostics and therapeutics. This funding enables us to accelerate the clinical development of our lead compounds, marking a significant step toward innovation and excellence in precision oncology.” Such enthusiasm sets a robust tone for the future progression of the company as it navigates new clinical phases with its advanced treatments.
About Angelini Ventures and NUCLIDIUM
Angelini Ventures operates as a crucial investment branch of Angelini Industries, focusing on nurturing disruptive innovations across BioTech and Digital Health landscapes. With plans for €300 million in investments, they aim to enhance their portfolio that currently covers diverse therapeutic areas, including developing leading companies in the field.
NUCLIDIUM AG is pioneering a newer generation of radiopharmaceuticals, innovatively using copper isotopes to revolutionize cancer diagnosis and therapy. The company combines expertise in clinical applications with advanced manufacturing techniques to ensure wide availability of clinically superior treatments. Their commitment is directed towards addressing unmet medical needs, particularly in oncology and women’s health, reinforcing their role as a pioneer in the field.
Frequently Asked Questions
What is the focus of Angelini Ventures?
Angelini Ventures focuses on investing in innovative companies in the BioTech and Digital Health sectors, aiming to accelerate disruptive technologies and solutions.
How much did Angelini Ventures invest in NUCLIDIUM?
Angelini Ventures co-led a CHF 79 million (approximately €84 million) Series B financing round for NUCLIDIUM.
What is NUCLIDIUM's primary area of expertise?
NUCLIDIUM specializes in developing next-generation copper-based radiopharmaceuticals aimed at improving cancer diagnosis and treatment.
Who will join NUCLIDIUM’s Board of Directors?
Regina Hodits, Managing Director at Angelini Ventures, will be joining NUCLIDIUM’s Board of Directors.
What is the significance of the Series B financing?
The Series B financing represents investor confidence in NUCLIDIUM's mission and supports the clinical development of its innovative therapies in oncology.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
